Home Page > Hearing - 110th Congress

HEARING

FDA’s Foreign Drug Inspection Program: Weaknesses Place Americans at Risk

Subcommittee on Oversight and Investigations
Tuesday, April 22, 2008, 11:00 a.m.
2123 Rayburn House Office Building

Hearing Webcast

(Any use of this recording is subject to Rule XI, 4 of the House of Representatives. See text of Rule XI, 4 as posted by the House Committee on Rules.)

Connect to the Archived Video Webcast of this Hearing or Download

Windows Media Player is required to view Committee Web casts.
Note: A version for Mac users is available on Microsoft's Web site.

Witness List & Prepared Testimony

Please click on the name of the witness to link to their prepared testimony. The testimony is available in Adobe pdf file format.

Panel I
The Honorable Andrew C. von Eschenbach, M.D. Commissioner Food and Drug Administration U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 Powerpoint Slides
Panel II
Gail H. Cassell, Ph.D. Vice President, Scientific Affairs Distinguished Lilly Research Scholar for Infectious Diseases Eli Lilly and Company Lilly Corporate Center, DC 1050 Indianapolis, IN 46285	Marcia G. Crosse, Ph.D. Director, Health Care U.S. Government Accountability Office 441 G Street, NW, Room 5K21 Washington, DC 20548 Powerpoint Slides
Mr. William Hubbard Senior Advisor Coalition for a Stronger FDA	Benjamin L. England, Esq. Benjamin L. England & Associates, LLC FDAImports.com, Inc. 8775 Centre Park Dr., Suite 265 Columbia, MD 21045
Mr. Carl R. Nielsen Director (Retired) Office of Regulatory Affairs Division of Import Operations Food and Drug Administration U.S. Department of Health and Human Services
Other Documents: Powerpoint slides

Hearing Transcript

Not available at this time. The printed hearing should be available within 90-120 days of the conclusion of the hearing. When available, the text of the printed hearing may be viewed at the U.S. Government Printing Office Web site.